Hormone Replacement Therapy

Perimenopause

What it looks like

Menopause

Menopause by definition is 12 consecutive months without a period. In the U.S. the average age is around 51. Menopause never stops, but the time after this year is often called postmenopause.After menopause occurs, estradiol and progesterone remain persistently low. Hot flashes and night sweats may continue for years — for a substantial minority of women, more than a decade.

Early or premature menopause — before 45, or before 40 (primary ovarian insufficiency) — and **surgical menopause** after removal of the ovaries deserve particular attention, because the health consequences of even more years without estrogen are significant.

If any of this is you, please come in.

GSM: genitourinary syndrome of menopause

GSM Genitourinary Symptoms of Menopause is the more modern term for what used to be called vaginal atrophy, or an even worse name senile vaginitis.

It describes the changes that occur throughout the vulvar, vaginal, urethral, and bladder tissues when estrogen is low.

These tissues are densely populated with estrogen receptors. Without adequate estrogen they become thinner, drier, less elastic, less vascular, and more fragile, and the local pH and microbiome shift.

Roughly half of postmenopausal women experience GSM, and the great majority never bring it up — because they assume it's inevitable, because no one asked, or because it feels too personal to raise in a fifteen-minute appointment.

Three things worth knowing.
First, GSM is progressive: unlike hot flashes, it typically worsens over time without treatment.
Second, it responds well to treatment, often dramatically.
Third, you do not actually have to be in menopause to experience GSM, it can happen during or just after pregnancy, and can be caused by some forms of birth control.

GSM isn't only a menopause problem

Hormonal contraception - Combined oral contraceptives suppress ovarian hormone production and substantially increase sex hormone binding globulin (SHBG), which binds up free testosterone. The result for some women is vaginal dryness, painful sex, and loss of libido that persists while on the pill — and occasionally for a period after stopping.

Progestin-only methods - The etonogestrel implant (Nexplanon — the successor to the discontinued Norplant), depot medroxyprogesterone (Depo-Provera), and hormonal IUDs can suppress estradiol enough in some women to cause genitourinary symptoms. Depo-Provera is the most consistently associated with a hypoestrogenic state.

Pregnancy, postpartum, and breastfeeding - Lactation suppresses estrogen substantially. Postpartum vaginal dryness and painful sex are extremely common, frequently dismissed, and very treatable — and they may persist for as long as you're nursing.

Cancer treatment - Chemotherapy, pelvic radiation, aromatase inhibitors, and GnRH agonists all induce low-estrogen states. Care in this setting is coordinated with your oncology team.

Other causes - Primary ovarian insufficiency, surgical removal of the ovaries, hypothalamic amenorrhea from low energy availability or overtraining, hyperprolactinemia, and endometriosis treatments.

Treatment options

Estradiol - The most effective treatment available for hot flashes and night sweats, and it addresses sleep, mood, joint pain, and genitourinary symptoms as well. Available orally or as a transdermal patch. Patches deliver estradiol through the skin, bypassing first-pass liver metabolism — a meaningful consideration for some women, particularly around clotting risk. *If you prefer patches, our Management & Coaching Only membership is usually the most economical route, since patches are typically well covered by insurance.*

Progesterone - If you still have a uterus and you're taking estrogen, progesterone is required to protect the uterine lining. It's also genuinely useful on its own — many women find it helps sleep, and in perimenopause it can steady heavy or erratic bleeding.

Testosterone for women - Women produce testosterone too, and levels decline with age. It's most established for low sexual desire that causes distress in postmenopausal women, and some women report benefits for energy and muscle. Two things to be clear about: there is currently **no FDA-approved testosterone product for women** in the United States, so this is prescribed off-label at female-physiologic doses, and it requires careful dosing and monitoring to avoid side effects such as acne, unwanted hair growth, or voice changes.

Vaginal estrogen for GSM - Low-dose estrogen delivered directly to the tissue — as a cream, tablet, or ring — restores thickness, elasticity, moisture, and blood flow where the problem actually is. Systemic absorption is minimal, so the risk profile is very different from systemic hormone therapy, and many women who can't or don't want to take systemic estrogen can still use it. It also reduces recurrent urinary tract infections in women who get them. This is frequently the single highest-impact thing we do for a patient, and it's available whether or not you're on systemic therapy.

Non-hormonal moisturizers and lubricants help with comfort during sex, but they don't reverse the underlying tissue changes. They're a complement, not a substitute.

Non-hormonal options - Hormone therapy isn't right for everyone, and some women simply prefer to avoid it. Effective non-hormonal approaches exist for vasomotor symptoms, sleep, and mood, including certain SSRIs and SNRIs, gabapentin, oxybutynin, and fezolinetant — a newer medication that targets the brain's temperature regulation directly without hormones. We'll discuss them honestly, including what the evidence actually supports.

Lifestyle work, included - Resistance training and 150+ minutes a week of activity to defend bone and muscle. Adequate protein, fiber, and calcium. Identifying and managing your personal hot flash triggers — often stress, alcohol, or caffeine. Sleep and stress strategies. This is part of your membership, not an upsell.

Risks, benefits, and the WHY

You have probably heard that hormone therapy causes breast cancer and heart attacks. That belief traces to early reporting of the Women's Health Initiative in 2002, and it caused a generation of women to be denied effective treatment.

The picture is more nuanced than the headlines were. Subsequent analysis showed that risk depends heavily on which hormones, which route, at what dose, and — critically — at what age and how long after menopause therapy begins. For most healthy women who are under 60 or within 10 years of menopause and who have bothersome symptoms, current guidance from major menopause societies holds that the benefits of systemic hormone therapy generally outweigh the risks.

Generally is not always. Hormone therapy can carries real risks. It is generally not recommended for women with a personal (not family) history of breast cancer, estrogen-sensitive cancer, unexplained vaginal bleeding, active or prior VTE caused by OCPs, active liver disease, or certain cardiovascular conditions.

What we do is have the actual conversation. Your personal and family history, your risk factors, your symptom burden, and what matters to you — then a decision you make with full information, revisited over time.